Repositorio Dspace

Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

Mostrar el registro sencillo del ítem

dc.contributor.author González-Barca, E
dc.contributor.author Canales, M
dc.contributor.author Salar, A
dc.contributor.author Ferreiro-Martínez, J-J
dc.contributor.author Ferrer-Bordes, S
dc.contributor.author García-Marco, J-A
dc.contributor.author Sánchez-Blanco, José-Javier
dc.contributor.author García-Frade, J
dc.contributor.author Penalver, J
dc.contributor.author Bello-López, J-L
dc.contributor.author Sancho, J-M
dc.contributor.author Caballero, D
dc.date.accessioned 2026-10-21T06:19:55Z
dc.date.available 2026-10-21T06:19:55Z
dc.date.issued 2016-05
dc.identifier.citation on behalf of the GELTAMO group, González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, et al. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. Ann Hematol. mayo de 2016;95(6):893-9. doi:10.1007/s00277-016-2648-4
dc.identifier.issn 0939-5555
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28882
dc.description.abstract The dissemination in the central nervous system (CNS) is an uncommon but fatal complication occurring in patients with diffuse large B-cell lymphoma (DLBCL). Standard prophylaxis has been demonstrated to reduce CNS relapse and improve survival rates. Intrathecal (IT) liposomal cytarabine allows maintaining elevated drug levels in the cerebrospinal fluid for an extended period of time. Data on the efficacy and safety of liposomal cytarabine as CNS prophylaxis in patients with DLBCL are still insufficient. The objective of the present study was to evaluate the effectiveness and safety of the prophylaxis with IT liposomal cytarabine in prevention of CNS relapse in high-risk patients with DLBCL who were included in a trial of first line systemic therapy with 6 cycles of dose-dense R-CHOP every 14 days. Twenty-four (18.6 %) out of 129 patients were identified to have risk factors for CNS involvement, defined as follows: >30 % bone marrow infiltration, testes infiltration, retroperitoneal mass ?10 cm, Waldeyer ring, or bulky cervical nodes involvement. Liposomal cytarabine (50 mg) was administered by lumbar puncture the first day of the 1st, 2nd, and 6th cycle of R-CHOP14 scheme. Among 70 IT infusions, grade 3-4 adverse events reported were headache (one patient) and nausea/vomiting (one patient). With a median follow-up of 40.1 months, no CNS involvement by DLBCL was observed in any patient. In conclusion, IT liposomal cytarabine is safe, feasible, and effective for CNS prophylaxis, causing few associated risks and little discomfort to patients with DLBCL.
dc.language.iso eng
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Adolescent
dc.subject.mesh Adult
dc.subject.mesh Aged
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Antibodies, Monoclonal, Murine-Derived/administration & dosage
dc.subject.mesh Antimetabolites, Antineoplastic/administration & dosage
dc.subject.mesh Antineoplastic Combined Chemotherapy Protocols/administration & dosage
dc.subject.mesh Cyclophosphamide/administration & dosage
dc.subject.mesh Cytarabine/administration & dosage
dc.subject.mesh Doxorubicin/administration & dosage
dc.subject.mesh Female
dc.subject.mesh Follow-Up Studies
dc.subject.mesh Humans
dc.subject.mesh Injections, Spinal
dc.subject.mesh Lymphoma, Large B-Cell, Diffuse/diagnosis/drug therapy/mortality
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Post-Exposure Prophylaxis/methods
dc.subject.mesh Prednisone/administration & dosage
dc.subject.mesh Prospective Studies
dc.subject.mesh Risk Factors
dc.subject.mesh Rituximab
dc.subject.mesh Survival Rate
dc.subject.mesh Vincristine/administration & dosage
dc.subject.mesh Young Adult
dc.title Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 27025508
dc.relation.publisherversion http://link.springer.com/10.1007/s00277-016-2648-4
dc.identifier.doi 10.1007/s00277-016-2648-4
dc.journal.title Annals of Hematology
dc.identifier.essn 1432-0584


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta